ID   DIF9
AC   CVCL_UF15
DR   Wikidata; Q93527528
RX   PubMed=2580049;
RX   PubMed=2937878;
CC   Population: African; Kenyan.
CC   Characteristics: Resistant to both the antiviral and antiproliferative actions of interferons.
CC   Sequence variation: MYC-IGH gene fusion (from parent cell line).
CC   Sequence variation: Homozygous for B2M p.Met1Ile (c.3G>C) (from parent cell line).
CC   Sequence variation: Homozygous for CTNNB1 p.Ala5_Ala80del (c.14_241del228) (from parent cell line).
CC   Sequence variation: Heterozygous for TP53 p.Gly266Glu (c.797G>A) (ClinVar=VCV000161516) (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0008 ! Daudi
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 02-07-20; Version: 4
//
RX   PubMed=2580049; DOI=10.1099/0022-1317-66-4-787;
RA   Dron M., Tovey M.G., Eid P.;
RT   "Isolation of Daudi cells with reduced sensitivity to interferon. III.
RT   Interferon-induced proteins in relation to the phenotype of interferon
RT   resistance.";
RL   J. Gen. Virol. 66:787-795(1985).
//
RX   PubMed=2937878; DOI=10.1099/0022-1317-67-4-663;
RA   Dron M., Tovey M.G., Uze G.;
RT   "Isolation of Daudi cells with reduced sensitivity to interferon. IV.
RT   Characterization of clones with altered binding of human interferon
RT   alpha subspecies.";
RL   J. Gen. Virol. 67:663-669(1986).
//